

Helga Gardarsdottir

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/298463/publications.pdf>

Version: 2024-02-01

91
papers

1,684
citations

331670

21
h-index

330143

37
g-index

93
all docs

93
docs citations

93
times ranked

2233
citing authors

#	ARTICLE	IF	CITATIONS
1	Indications for antidepressant drug prescribing in general practice in the Netherlands. Journal of Affective Disorders, 2007, 98, 109-115.	4.1	141
2	Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. European Journal of Clinical Pharmacology, 2014, 70, 849-857.	1.9	135
3	Initiation of antidepressant therapy: do patients follow the GP's prescription?. British Journal of General Practice, 2009, 59, 81-87.	1.4	100
4	Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidemiology and Drug Safety, 2016, 25, 56-65.	1.9	96
5	Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. Journal of Clinical Epidemiology, 2010, 63, 422-427.	5.0	90
6	The High Impact of Penicillin Allergy Registration in Hospitalized Patients. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 926-931.	3.8	89
7	The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. Rheumatology, 2016, 55, 704-709.	1.9	45
8	Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study. British Journal of Clinical Pharmacology, 2020, 86, 1150-1164.	2.4	42
9	Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study. British Journal of Clinical Pharmacology, 2019, 85, 2524-2539.	2.4	41
10	Incidence Rates and Trends of Hip/Femur Fractures in Five European Countries: Comparison Using E-Healthcare Records Databases. Calcified Tissue International, 2014, 94, 580-589.	3.1	39
11	Duration of Antidepressant Drug Treatment and Its Influence on Risk of Relapse/Recurrence: Immortal and Neglected Time Bias. American Journal of Epidemiology, 2009, 170, 280-285.	3.4	38
12	Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related) project. Pharmacoepidemiology and Drug Safety, 2016, 25, 66-78.	1.9	34
13	An algorithm to identify antidepressant users with a diagnosis of depression from prescription data. Pharmacoepidemiology and Drug Safety, 2009, 18, 7-15.	1.9	32
14	Pharmacists' Activities to Reduce Medication Waste: An International Survey. Pharmacy (Basel), 2020, 16, 32.	1.6	32
15	Potential bias in pharmacoepidemiological studies due to the length of the drug free period: a study on antidepressant drug use in adults in the Netherlands. Pharmacoepidemiology and Drug Safety, 2006, 15, 338-343.	1.9	28
16	Redispensing of medicines unused by patients: a qualitative study among stakeholders. International Journal of Clinical Pharmacy, 2017, 39, 196-204.	2.1	27
17	Patient and medication factors associated with preventable medication waste and possibilities for redispensing. International Journal of Clinical Pharmacy, 2018, 40, 704-711.	2.1	27
18	Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer's disease. European Neuropsychopharmacology, 2018, 28, 1260-1269.	0.7	26

#	ARTICLE	IF	CITATIONS
19	Methodological comparison of marginal structural model, time-varying Cox regression, and propensity score methods: the example of antidepressant use and the risk of hip fracture. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 114-121.	1.9	24
20	The Impact of Inadequate Temperature Storage Conditions on Aggregate and Particle Formation in Drugs Containing Tumor Necrosis Factor-Alpha Inhibitors. <i>Pharmaceutical Research</i> , 2018, 35, 42.	3.5	24
21	Opportunities and Challenges for Decentralized Clinical Trials: European Regulators's Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 344-352.	4.7	24
22	Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 88-102.	1.9	23
23	Exploring the Association between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: A VigiBase Study. <i>Drug Safety</i> , 2019, 42, 887-895.	3.2	23
24	Does the Length of the First Antidepressant Treatment Episode Influence Risk and Time to a Second Episode?. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 69-72.	1.4	22
25	Willingness of patients to use unused medication returned to the pharmacy by another patient: a cross-sectional survey. <i>BMJ Open</i> , 2019, 9, e024767.	1.9	22
26	Quantity and economic value of unused oral anti-cancer and biological disease-modifying anti-rheumatic drugs among outpatient pharmacy patients who discontinue therapy. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 100-105.	3.0	22
27	Seasonal patterns of initiating antidepressant therapy in general practice in the Netherlands during 2002-2007. <i>Journal of Affective Disorders</i> , 2010, 122, 208-212.	4.1	21
28	Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 310-320.	4.7	21
29	Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 988-1000.	2.4	19
30	Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries. <i>Cytotherapy</i> , 2020, 22, 592-600.	0.7	18
31	Do patients initiate therapy? Primary non-adherence to statins and antidepressants in Iceland. <i>International Journal of Clinical Practice</i> , 2015, 69, 597-603.	1.7	17
32	What does it cost to redispense unused medications in the pharmacy? A micro-costing study. <i>BMC Health Services Research</i> , 2019, 19, 243.	2.2	17
33	Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population-based cohort studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1339-1352.	1.9	17
34	Older Patients's Compliance with Drug Storage Recommendations. <i>Drugs and Aging</i> , 2018, 35, 233-241.	2.7	16
35	Measuring the impact of pharmacovigilance activities, challenging but important. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2235-2237.	2.4	14
36	Prescribing patterns and compliance with World Health Organization recommendations for the management of severe malaria: a modified cohort event monitoring study in public health facilities in Ghana and Uganda. <i>Malaria Journal</i> , 2019, 18, 36.	2.3	14

#	ARTICLE	IF	CITATIONS
37	Antidepressants in primary care: patients' experiences, perceptions, self-efficacy beliefs, and nonadherence. <i>Patient Preference and Adherence</i> , 2014, 8, 179.	1.8	12
38	Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 79-87.	1.9	12
39	Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 594549.	3.5	12
40	COVID-19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1517-1527.	4.7	12
41	The Association Between Patient-Reported Drug Taking and Gaps and Overlaps in Antidepressant Drug Dispensing. <i>Annals of Pharmacotherapy</i> , 2010, 44, 1755-1761.	1.9	11
42	Primary-care patients' trade-off preferences with regard to antidepressants. <i>Psychological Medicine</i> , 2014, 44, 2301-2308.	4.5	11
43	Case-only designs for studying the association of antidepressants and hip or femur fracture. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 103-113.	1.9	11
44	Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 154, 105501.	4.0	11
45	Drug exposure misclassification in pharmacoepidemiology: Sources and relative impact. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1703-1715.	1.9	11
46	A systematic review of how missing data are handled and reported in <scp>multi-database</scp> pharmacoepidemiologic studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 819-826.	1.9	10
47	New-user and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 960-974.	1.9	8
48	Implementation and performance of haemovigilance systems in 10 sub-saharan African countries is sub-optimal. <i>BMC Health Services Research</i> , 2021, 21, 1258.	2.2	8
49	Prevalence of Medication Use for Somatic Disease in Institutionalized Psychiatric Patients. <i>Pharmacopsychiatry</i> , 2013, 46, 274-280.	3.3	7
50	Associations Between Personality Traits and Adherence to Antidepressants Assessed Through Self-Report, Electronic Monitoring, and Pharmacy Dispensing Data. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 465-471.	1.4	7
51	Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008-2015). <i>Frontiers in Pharmacology</i> , 2021, 12, 682890.	3.5	7
52	Regulating advanced therapy medicinal products through the Hospital Exemption: an analysis of regulatory approaches in nine EU countries. <i>Regenerative Medicine</i> , 2020, 15, 2015-2028.	1.7	7
53	Instrumental variables analysis using multiple databases: an example of antidepressant use and risk of hip fracture. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 122-131.	1.9	6
54	Actual versus recommended storage temperatures of oral anticancer medicines at patients' homes. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 382-389.	0.9	6

#	ARTICLE	IF	CITATIONS
55	Building HTA insights into the drug development plan: Current approaches to seeking early scientific advice from HTA agencies. <i>Drug Discovery Today</i> , 2022, 27, 347-353.	6.4	6
56	Transitions from General Practitioner to Psychiatrist Care (or vice versa) during a First Antidepressant Treatment Episode. <i>Pharmacopsychiatry</i> , 2010, 43, 179-183.	3.3	5
57	Selection of Blood, Blood Components, and Blood Products as Essential Medicines in 105 Low- and Middle-Income Countries. <i>Transfusion Medicine Reviews</i> , 2020, 34, 94-100.	2.0	5
58	Are Further Interventions Needed to Prevent and Manage Hospital-Acquired Hyponatraemia? A Nationwide Cross-Sectional Survey of IV Fluid Prescribing Practices. <i>Journal of Clinical Medicine</i> , 2020, 9, 2790.	2.4	5
59	Discontinuation of Somatic Medication During Psychiatric Hospitalization. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1415-1424.	1.9	4
60	Predicting rehospitalization in patients treated with antipsychotics: a prospective observational study. <i>Therapeutic Advances in Psychopharmacology</i> , 2018, 8, 213-229.	2.7	4
61	Safety Experience During Real-World Use of Injectable Artesunate in Public Health Facilities in Ghana and Uganda: Outcomes of a Modified Cohort Event Monitoring Study (CEMISA). <i>Drug Safety</i> , 2018, 41, 871-880.	3.2	4
62	Distinct Profiles on Subjective and Objective Adherence Measures in Patients Prescribed Antidepressants. <i>Drugs</i> , 2019, 79, 647-654.	10.9	4
63	Redispensing of unused HIV post-exposure prophylaxis for medical students. <i>Travel Medicine and Infectious Disease</i> , 2019, 29, 82-83.	3.0	4
64	Post-marketing dosing changes in the label of biologicals. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 715-721.	2.4	4
65	Regulatory Safety Learning Driven by the Mechanism of Action: The Case of TNF Inhibitors. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 123-131.	4.7	4
66	Quality of reporting of drug exposure in pharmacoepidemiological studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1141-1150.	1.9	4
67	Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. <i>Pharmaceuticals</i> , 2021, 14, 189.	3.8	4
68	Enabling appropriate use of antibiotics: review of European Union procedures of harmonising product information, 2007 to 2020. <i>Eurosurveillance</i> , 2020, 25, .	7.0	4
69	Discontinuation of anticoagulant care during admission to a psychiatric hospital. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1025-1029.	1.9	3
70	Medication Discontinuation in Patients After Discharge From a Psychiatric Hospital. <i>Annals of Pharmacotherapy</i> , 2015, 49, 1085-1095.	1.9	3
71	Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban – A European comparative drug utilization study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 440-454.	2.5	3
72	The effect of non-adherence to antipsychotic treatment on rehospitalization in patients with psychotic disorders. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532110274.	2.7	3

#	ARTICLE	IF	CITATIONS
73	Switching TNF \pm inhibitors: Patterns and determinants. Pharmacology Research and Perspectives, 2021, 9, e00843.	2.4	3
74	Indications related to antidepressant prescribing in the Nivel-PCD database and the SIDIAP database. Journal of Affective Disorders, 2022, 303, 131-137.	4.1	3
75	Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions. Pharmacoepidemiology and Drug Safety, 2019, 28, 1563-1571.	1.9	2
76	Associations between personality traits and adequate home storage of drugs in older patients. Psychology, Health and Medicine, 2019, 24, 1255-1266.	2.4	2
77	Publication rates and reported results in a cohort of gene- and cell-based therapy trials. Regenerative Medicine, 2020, 15, 1215-1227.	1.7	2
78	Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study. Biologicals, 2021, 69, 30-37.	1.4	2
79	Antipsychotic Use and the Risk of Initiating Medication for Benign Prostate Hyperplasia in Persons With Alzheimer Disease. Journal of Clinical Psychopharmacology, 2018, 38, 494-497.	1.4	1
80	Adverse events related to biologicals used for patients with multiple sclerosis: a comparison between information originating from regulators and information originating from the scientific community. European Journal of Neurology, 2020, 27, 1250-1256.	3.3	1
81	Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety Signals. Drug Safety, 2021, 44, 589-600.	3.2	1
82	Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants. British Journal of Clinical Pharmacology, 2021, 87, 3508-3517.	2.4	1
83	A cross-sectional survey of knowledge pertaining to IV fluid therapy and hyponatraemia among nurses working at emergency departments in Denmark. International Emergency Nursing, 2021, 57, 101010.	1.5	1
84	Impact of regulatory interventions to restrict the combined use of renin-angiotensin system-affecting agents: A Danish nationwide drug utilisation study. British Journal of Clinical Pharmacology, 2021, , .	2.4	1
85	Nature and timing of post-approval manufacturing changes of tumour necrosis factor \pm inhibitor products: A 20-year follow-up study of originators and biosimilars. European Journal of Pharmaceutical Sciences, 2022, 175, 106227.	4.0	1
86	Gardarsdottir et al. Respond to "Assessing Treatment Effects With Observational Analyses". American Journal of Epidemiology, 2009, 170, 288-288.	3.4	0
87	The association between lifting an administrative restriction on antidepressant dispensing and treatment patterns in Iceland. Health Policy, 2013, 111, 193-199.	3.0	0
88	Measuring Drug use: differences between medical records and Healthcare Utilisation Databases. Clinical Therapeutics, 2015, 37, e75.	2.5	0
89	SAT0161...Majority of Patients do not Store Their Biological Disease Modifying Antirheumatic Drugs Within Recommended Temperature Range. Annals of the Rheumatic Diseases, 2015, 74, 710.2-711.	0.9	0
90	Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept. BioDrugs, 2021, 35, 765-772.	4.6	0

#	ARTICLE	IF	CITATIONS
91	The association between patient satisfaction with information and adherence to oral anticancer agents. Journal of Oncology Pharmacy Practice, 2023, 29, 637-645.	0.9	0